RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biohaven Pharmaceutical Holding Company Stock

Biohaven Pharmaceutical Holding Company Equity 2024

Biohaven Pharmaceutical Holding Company Equity

427.98 M USD

Ticker

BHVN

ISIN

VGG111961055

WKN

A2DQ7W

In 2024, Biohaven Pharmaceutical Holding Company's equity was 427.98 M USD, a -20.57% increase from the 538.8 M USD equity in the previous year.

Biohaven Pharmaceutical Holding Company Aktienanalyse

What does Biohaven Pharmaceutical Holding Company do?

Biohaven Pharmaceutical is a biopharmaceutical company focused on developing innovative therapies for neurological disorders. It was founded in 2013 and is headquartered in New Haven, Connecticut. The company's business model is based on discovering and developing novel medications for conditions such as migraine, spinal muscular atrophy, Alzheimer's, and other neurological disorders. Biohaven invests in research and development to create therapies that can enhance patients' lives. It has divisions dedicated to developing treatments for migraine, neurodegeneration, and spinal muscular atrophy. Biohaven's first product, Rimegepant, is a migraine medication that inhibits the CGRP receptor. It has been approved in the US for migraine treatment. Troriluzol, another migraine medication, is still in clinical development. Biohaven is also active in the fields of Alzheimer's and ALS, with medications like BHV-0223 and BHV-4157 in development. The company aims to develop innovative medications that can improve and restore patient health. It collaborates with other companies and research institutions to maximize its research potential and bring innovative therapies to market faster. Overall, Biohaven Pharmaceutical is a leading biopharmaceutical company dedicated to developing innovative therapies for neurological disorders, with a strong pipeline of medications and a committed research and development department working towards improving global patient healthcare. Biohaven Pharmaceutical Holding Company ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Biohaven Pharmaceutical Holding Company's Equity

Biohaven Pharmaceutical Holding Company's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biohaven Pharmaceutical Holding Company's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biohaven Pharmaceutical Holding Company's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biohaven Pharmaceutical Holding Company's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biohaven Pharmaceutical Holding Company’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biohaven Pharmaceutical Holding Company stock

What is the equity of Biohaven Pharmaceutical Holding Company this year?

Biohaven Pharmaceutical Holding Company has equity of 427.98 M USD this year.

What was the equity of Biohaven Pharmaceutical Holding Company compared to the previous year?

The equity of Biohaven Pharmaceutical Holding Company has increased/decreased by -20.57% decreased compared to the previous year.

What impact does a high equity have on investors of Biohaven Pharmaceutical Holding Company?

A high equity is advantageous for investors of Biohaven Pharmaceutical Holding Company as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Biohaven Pharmaceutical Holding Company?

A low equity can be a risk for investors of Biohaven Pharmaceutical Holding Company, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Biohaven Pharmaceutical Holding Company affect the company?

An increase in equity of Biohaven Pharmaceutical Holding Company can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Biohaven Pharmaceutical Holding Company affect the company?

A reduction in equity of Biohaven Pharmaceutical Holding Company can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Biohaven Pharmaceutical Holding Company?

Some factors that can affect the equity of Biohaven Pharmaceutical Holding Company include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Biohaven Pharmaceutical Holding Company so important for investors?

The equity of Biohaven Pharmaceutical Holding Company is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Biohaven Pharmaceutical Holding Company take to change the equity?

To change equity, Biohaven Pharmaceutical Holding Company can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Biohaven Pharmaceutical Holding Company pay?

Over the past 12 months, Biohaven Pharmaceutical Holding Company paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biohaven Pharmaceutical Holding Company is expected to pay a dividend of 0 USD.

What is the dividend yield of Biohaven Pharmaceutical Holding Company?

The current dividend yield of Biohaven Pharmaceutical Holding Company is .

When does Biohaven Pharmaceutical Holding Company pay dividends?

Biohaven Pharmaceutical Holding Company pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biohaven Pharmaceutical Holding Company?

Biohaven Pharmaceutical Holding Company paid dividends every year for the past 0 years.

What is the dividend of Biohaven Pharmaceutical Holding Company?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biohaven Pharmaceutical Holding Company located?

Biohaven Pharmaceutical Holding Company is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biohaven Pharmaceutical Holding Company kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biohaven Pharmaceutical Holding Company from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Biohaven Pharmaceutical Holding Company pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Biohaven Pharmaceutical Holding Company in the year 2023?

In the year 2023, Biohaven Pharmaceutical Holding Company distributed 0 USD as dividends.

In which currency does Biohaven Pharmaceutical Holding Company pay out the dividend?

The dividends of Biohaven Pharmaceutical Holding Company are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biohaven Pharmaceutical Holding Company

Our stock analysis for Biohaven Pharmaceutical Holding Company Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biohaven Pharmaceutical Holding Company Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.